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E. Bottieau1, Tammy Hoffmann13 and Paul N. Newton2,3,4,15 
Abstract 
Over recent years, the research community has been increasingly using preprint servers to share manuscripts that are 
not yet peer-reviewed. Even if it enables quick dissemination of research findings, this practice raises several chal-
lenges in publication ethics and integrity. In particular, preprints have become an important source of information 
for stakeholders interested in COVID19 research developments, including traditional media, social media, and policy 
makers. Despite caveats about their nature, many users can still confuse pre-prints with peer-reviewed manuscripts. If 
unconfirmed but already widely shared first-draft results later prove wrong or misinterpreted, it can be very difficult to 
“unlearn” what we thought was true. Complexity further increases if unconfirmed findings have been used to inform 
guidelines. To help achieve a balance between early access to research findings and its negative consequences, we 
formulated five recommendations: (a) consensus should be sought on a term clearer than ‘pre-print’, such as ‘Unref-
ereed manuscript’, “Manuscript awaiting peer review” or ‘’Non-reviewed manuscript”; (b) Caveats about unrefereed 
manuscripts should be prominent on their first page, and each page should include a red watermark stating ‘Cau-
tion—Not Peer Reviewed’; (c) pre-print authors should certify that their manuscript will be submitted to a peer-review 
journal, and should regularly update the manuscript status; (d) high level consultations should be convened, to 
formulate clear principles and policies for the publication and dissemination of non-peer reviewed research results; 
(e) in the longer term, an international initiative to certify servers that comply with good practices could be envisaged.
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. The Creative Commons Public Domain Dedication waiver (http:// creat iveco 
mmons. org/ publi cdoma in/ zero/1. 0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Over recent years, the research community has been 
increasingly using preprint servers to share manuscripts 
that have not yet been peer-reviewed, enabling quick dis-
semination of research findings, and in some cases to 
obtain peer feedback to improve the final version sub-
mitted to a journal [1]. Relevant international stakehold-
ers provide guidance on ethics and integrity in scientific 
publications, in particular the Committee on Publica-
tion Ethics (COPE) and the International Committee of 
Medical Journal Editors (ICMJE). However, issues related 
to publication ethics and integrity become more compli-
cated, when a form of publication has already occurred 
before peer review and is available to the public. Fur-
thermore, calls to rapidly share research results to 
inform public health emergencies including COVID19, 
have introduced additional layers of complexity [2–4]. 
For instance, according to the World Health Organiza-
tion (WHO) Working Group on Ethics and COVID19, 
researchers generating information with the potential to 
aid response efforts have an ethical obligation to share 
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it “without waiting for publication in scientific journals”, 
and as soon as the information “is quality-controlled for 
release (e.g., peer-reviewed)” [5]. These recommenda-
tions have an inherent conflict, as the quality control of 
the peer-review process is managed by the scientific jour-
nals whose publication timelines should not be waited 
for. The pursuit of rapid dissemination also comes into 
conflict with the need to comply with adequate publica-
tion standards [2].
Preprint platforms: benefits and risks
Preprints (i.e. preliminary reports of work not yet subject 
to peer review) are increasingly posted online on web-
sites such as the well-known MedRxiv, arXiv and bioRxiv 
[6–8], as well as other servers. These can be valuable 
mechanisms to facilitate rapid communication within 
the international scientific community, and trigger early, 
fruitful and transparent discussion among peers, while 
waiting for the scientific work to undergo a journal’s 
peer review. A cross-sectional study of preprint policies 
among the 100 clinical journals with the highest impact 
factors showed that 86% of journals allow for submit-
ted articles to be previously posted as preprints, making 
researchers less concerned that posting a manuscript on a 
preprint server will disqualify it from further publication 
[1]. However, it remains important to thoroughly under-
stand and accurately describe the nature and purpose of 
preprints. This is why arXiv explicitly states that mate-
rial is “not peer-reviewed by arXiv” and” they should not 
be relied upon without context to guide clinical practice 
or health-related behavior and should not be reported 
in news media as established information without con-
sulting multiple experts in the field” [7]; and bioRxiv 
clarifies that “articles are not peer-reviewed, edited, or 
typeset before being posted online” [8]. Preprints posted 
in MedRxiv, arXiv and bioRxiv include a small header or 
footer on each page with a warning that the article has 
not undergone peer review [6–8]. MedRxiv also explic-
itly states that due to the inherent nature of “prelimi-
nary reports of work that have not been certified by peer 
review”, preprints “should not be relied on to guide clini-
cal practice or health-related behavior and should not be 
reported in news media as established information” [6]. 
This is an important caveat as there is no assurance that 
preprints have not had any external quality control when 
they are made publicly available. However, it is unlikely 
that it will always be carefully read—for instance, when 
preprints are circulated via social media.
Though peer review remains the de facto source of 
quality-assurance in scientific publishing [9], it does 
not always prevent inaccurate reports from entering 
the scientific literature [10–12], and mechanisms to 
ensure reviewer access to original data sets or codes for 
analysis to strengthen the quality of review are not sys-
tematically in place. This has become particularly evi-
dent during the pandemic. Smith and colleagues noted 
in March 2021 that in a rush to disseminate information 
about COVID19, diverse inaccuracies have been pub-
lished, causing inappropriate changes in clinical care, 
ineffective public health responses, and increasing anxi-
ety in communities [13]. It is also likely that the rush to 
publish COVID19 manuscripts is causing shortages of 
qualified reviewers. The vast and growing volume of sub-
missions related to COVID19 is precipitating reviewer 
fatigue. Despite the limitations, peer review can help to 
mitigate overinterpretation and misreporting of results, 
and reduce the proportion of poor-quality and inaccu-
rate publications [11–13]. Therefore, when it comes to 
pre-prints, both authors and readers would benefit from 
guidance about their appropriate dissemination and 
interpretation, and on reliable servers for posting and 
finding preprints.
The WHO has established a platform bringing together 
approved clinical trial registries [14], and a similar initia-
tive for pre-print servers may be necessary. The Commit-
tee on Publication Ethics (COPE) and the International 
Committee of Medical Journal Editors (ICMJE) could 
play an essential role in setting high ethical standards for 
reporting and disseminating research findings—includ-
ing those that have not yet been peer-reviewed-, intend-
ing to promote integrity along all phases of research 
dissemination.
Preprints: what’s in a name
Despite the caveats provided in various servers, preprints 
can still be confused with peer-reviewed manuscripts. 
The name “pre-print” itself may further encourage mis-
understanding. The term implies that the manuscript will 
be printed or published, thus inferring a level of quality 
sufficient for publication. It may also raise expectations 
that the manuscript should, or ever will in any case be 
printed. Additionally, “pre-print” sounds very close to 
“Epub ahead of print", which indicates a peer-reviewed 
article that is being listed electronically before being 
typeset [15].
For some users, especially those who are not involved 
in the scientific publishing process, such as journalists, 
politicians, policy-makers, and the general public, this 
language implicitly suggests a sort of imprimatur, i.e. 
that the contents have already be approved, which may 
increase the probability that they are widely promoted 
and disseminated before a robust external evaluation. A 
clearer term should be chosen instead of ‘preprint’, such 
as ‘Unrefereed manuscript’ or “Manuscript awaiting peer 
review” or ‘’Non-reviewed manuscript”, to avoid prevent-
able misunderstandings.
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Hunger for scientific information in times of COVID19
The COVID19 pandemic has created a global “hunger” 
for scientific information to inform policy and the gen-
eral public. In the 5  months prior to the COVID19 era 
(1/8/2019 to 31/12/2019), 14,078 preprints were posted 
in MedRxiv and bioRxiv. This number increased by 
61.2% to 22,691 in the first 5-months of the COVID19 
era (1/1/2020 to 31/5/2020), including both COVID19 
and non-COVID19-related preprints. Preprints have 
become an important source of information for a variety 
of stakeholders interested in COVID19 research devel-
opments, including traditional media, social media, and 
policy-makers. But the philosophy of preprints, i.e. that 
errors will get fixed over time as the scientific commu-
nity crowdsources and opines on the findings [22], may 
be unknown to or misunderstood by many of their new 
users, including politicians, journalists, “influencers”, pre-
scribers, policy-makers—and sometimes even research-
ers. Nowadays, research appraisal and synthesis often 
occur before a decision is reached on publication, with 
the risk of leading to “irresponsible dissemination, as 
flawed studies are picked up by the media” [2]. For exam-
ple, suppose clinical trial findings are only available as 
preprints. In that case, a cautionary approach should be 
taken to the interpretation of their findings, which should 
not be used as the sole basis for introducing a new thera-
peutic or preventive intervention into practice and policy. 
Lack of caution may have been a factor in the publica-
tion and withdrawal of early evidence on hydroxychlo-
roquine efficacy in COVID19 [16–20]. Numerous papers 
related to COVID19 cite preprint materials, and it is not 
always explicitly stated that these are not peer-reviewed 
and should be cautiously and critically interpreted [21]. 
Additionally, if unconfirmed but widely shared first-
draft results later prove to be wrong or misinterpreted, 
it can be very difficult for people to “unlearn” what they 
thought was true [22], because of ‘anchoring bias’, which 
comes into play when individuals prioritize informa-
tion and data that support their initial impressions, even 
when first impressions are wrong [23]. Complexity may 
further increase if such unconfirmed findings had been 
used to inform guidelines; and if pre-prints remain pre-
prints indefinitely and never get formally published, 
either because they are rejected or not even submitted.
We need a balance between early access to research 
findings and its unwanted negative consequences, such 
as the rushed adoption of policies unsupported by evi-
dence on efficacy and safety, and misplaced or unreal-
istic expectations from the public, policy-makers and 
stakeholders [16, 24–27]. Therefore, we contend that all 
preprint servers should state, as does MedRxiv [6], that 
“Preprints are preliminary reports of work that have not 
been certified by peer review. They should not be relied 
on to guide clinical practice or health-related behaviour 
and should not be reported in news media as established 
information”. The caveat should not be divorced from 
preprints when they circulate, thus this statement should 
be prominent on the first page of each preprint, and each 
page should include a red watermark stating ‘Caution—
Not Peer-Reviewed’ [10, 15]. This call is in line with a 
statement from the Editors of The Lancet, who con-
firmed the journal policy to make preprints a permanent 
offering, while applying “a more obvious watermark stat-
ing that these are preprints and not peer-reviewed” [28].
A call for scientific integrity standards
While preprints can help to make new evidence-based 
knowledge rapidly available to the scientific commu-
nity, and perhaps improve scientific transparency [15], 
these benefits can be undermined by harms caused by 
the release, dissemination, and misuse of unreliable evi-
dence. It is not a foregone conclusion that the potential 
benefits of preprints always outweigh the risks of harm 
[10, 29]. It is also crucial that preprints are accompanied 
by a minimal set of essential, ethics-related information. 
However, this is not always the case. For instance, only 
two-thirds of research paper authors who submitted to 
the Lancet Group journals and opted to post pre-prints 
at submission, had posted all this information, i.e. eth-
ics approval if needed, declaration of interests, funding 
statement, and prospective registration for randomised 
controlled trials [28]. Thus, the various stakeholders 
that currently encourage the use of ‘preprints’, including 
research institutions and research funding agencies [30], 
should also encourage improvement of ethical standards, 
appropriate terminology, warnings regarding interpreta-
tion and dissemination, and recognition of limitations. 
Given the rapid and growing importance and use of pre-
print servers, particularly concerning the ongoing pan-
demic, the time is ripe for the scientific community to 
agree on “Good Preprint Practices” formally. Adequate 
and harmonized scientific quality and integrity standards 
[10] should be defined, as they have been for other criti-
cal research and reporting activities [31], and appropri-
ate mechanisms for implementation and enforcement 
of such good practices should be identified and imple-
mented. In particular, we propose the following specific 
recommendations:
• As the term “preprint” may cause misunderstanding 
about the nature of these manuscripts, consensus 
should be urgently sought on a clearer term, such 
as ‘Unrefereed manuscript’ or “Manuscript awaiting 
peer review” or ‘’Non-reviewed manuscript”.
• Key caveats about unrefereed manuscripts (i.e., that 
they are preliminary reports of work that have not 
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been subject to peer review; that they should not be 
relied on to guide clinical practice or health-related 
behaviour; and that they should not be reported in 
news media as established information), should be 
prominent on the first page of each preprint, and 
each page should include a red watermark stating 
‘Caution—Not Peer Reviewed’.
• Pre-print servers should require authors to certify 
that the manuscript will imminently be -or is- sub-
mitted to a peer review journal; to regularly update 
the status of the manuscript (e.g. submitted, rejected, 
re-submitted, published with DOI); and to disclose 
their pre-print history.
• High level consultations should be convened with 
relevant stakeholders, including but not limited to 
the ICMJE, COPE and WHO, to formulate clear 
principles and policies for the publication and dis-
semination of non peer-reviewed research results, 
and to further disseminate such principles and poli-
cies to the scientific community.
• In the longer term, an initiative to certify servers that 
comply with agreed good practices could be envis-
aged.
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